Their patented intravenous agent, EVP1001, targets metabolically active cells and provides superior diagnostic accuracy and earlier assessment of therapy response. It distinguishes healthy from abnormal tissue in a single, noninvasive exam, avoiding radiation and radioactive agents. The technology has been validated for evaluating cancer, chronic liver disease, heart disease, and stem cell therapy for the heart. Additionally, the company is testing the agent for cardiac perfusion, function, and vessel status, which currently require multiple expensive tests. Preclinical data also supports its use in imaging solid tumors in breast cancer and hepatic disease.